Australia’s National Health and Medical Research Council (NHMRC) released interim advice on puberty blockers Monday, Nov. 16. Its Gender Guidelines Development Committee says the drugs should remain a clinical option for some trans and gender diverse young people who have started puberty. It made a conditional recommendation, reflecting both the low certainty of the evidence and the need for individual decisions.
The advice is open for public consultation and does not require states or territories to change their health policies.
Comments are open until 1 p.m. AEDT on Jan. 18, 2027, through the NHMRC consultation page.
Source: National Health and Medical Research Council. The document is draft advice released for public consultation.
What the NHMRC Puberty Blockers Advice Says
According to the ABC, the committee reviewed 15 non-randomized studies and rated the overall certainty of the evidence as low. Most followed young people for six months to two years.
“A conditional recommendation is made in cases where shared decision-making is essential because different options may be appropriate for different individuals and they might make different choices, or where the overall certainty of available evidence is low. Both are the case here,” the report says, as quoted by the ABC.
The advice covers young people with gender incongruence, with or without distress, who have begun puberty and are assessed as suitable. Decisions should involve the young person, their parents or carers, and clinicians. “Not all young people will want or need the same intervention at the same time or age,” the committee wrote.
The review found no eligible studies reporting fertility potential, fractures or other functional measures of bone health. That is a gap within the review’s criteria, not evidence that treatment has no effect on those outcomes. The advice itself calls for a comprehensive health assessment before treatment and regular monitoring, including bone mineral density.
“Puberty suppressants are one possible part of care,” NHMRC acting CEO Prue Torrance said, according to NCA NewsWire. She said decisions “need to be made through shared decision making that involves the individual young person, their parents or carers and clinicians.”
What the Advice Means for States
Two days after Queensland paused new treatment in January 2025, Health Minister Mark Butler announced the review. He has told the ABC he expects state and territory governments to give the advice “proper consideration.”
In his Monday statement, Butler said states and territories are responsible for delivering public gender services. The Commonwealth does not control their clinical policies.
Queensland and Northern Territory Restrictions Remain
None of this binds state health systems. Queensland’s pause on new hormone treatment for trans patients under 18 in its public hospitals began in January 2025, and Queensland Health Minister Tim Nicholls extended it in December 2025 after a review led by Ruth Vine, Victoria’s former chief psychiatrist.
“This pause will remain in place until the results of the PATHWAYS TRIAL in the United Kingdom are known in 2031,” his Dec. 19 statement said. Existing patients keep their treatment through Children’s Health Queensland, the statement said.
The Northern Territory went further two days later. It stopped publicly funding puberty blockers and gender-affirming hormones for children, the ABC reported on Dec. 21, 2025.
Queensland and the Northern Territory said their restrictions would remain, The Guardian reported Monday.
Trans Youth Advocates Push Queensland and the NT to Change Course
“Queensland and the Northern Territory must lift their bans to allow young people, their families and clinicians to make these decisions together,” Equality Australia CEO Anna Brown said in a statement Monday.
“No young person’s access to clinically appropriate healthcare should depend on which state they live in,” Brown said.
Susanne Prosser, CEO of Transcend, said the families it supports feel worn down. “Many of the families we support tell us they feel like they are constantly having to justify their child’s existence, their child’s identity, or their child’s right to healthcare,” she said in the same release.
How to Comment on the Puberty Suppressants Advice
Anyone can respond through the NHMRC’s Share your views form. “Submissions should address the content of the Advice on Puberty Suppressants, including the proposed recommendation and good practice statements,” the consultation page says.
The council is seeking feedback on the evidence, recommendation and good practice statements. It plans to publish an anonymized report on the responses.
“The full guidelines are expected to be released for public consultation by early 2028,” the council says. Those guidelines will cover hormones and psychosocial support for trans and gender diverse people under 18.




